Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00159614 · ClinicalTrials.gov registry record · Phase 2
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
A Phase 2 study, sponsored by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00159614: Completed Phase 2 study, sponsored by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
NCT00159614 is a Phase 2 study that has completed, run by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00159614, a Phase 2 study, has completed, sponsored by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.
Interventions
- DRUG KW-3902IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-09 |
| Phase | Phase 2 |
What the finished NCT00159614 record still lists
NCT00159614 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which KW-3902IV is the first listed.
NCT00159614 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00159614 about?
NCT00159614 is a clinical study titled "Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment". The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.
What is the current status of trial NCT00159614?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-09.
What interventions are being tested in trial NCT00159614?
The interventions under investigation include: KW-3902IV (DRUG).
Who is sponsoring clinical trial NCT00159614?
This trial is sponsored by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00159614's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia